Osteologix Inc. and Servier Announce Ex-US Licensing Agreement

GLEN ALLEN, Va. & NEUILLY, France--(BUSINESS WIRE)--Osteologix, Inc. (OTCBB: OLGX) through its wholly owned Irish subsidiary Osteologix Limited and the Servier Research Group, the leading French independent pharmaceutical company, today announced that Osteologix has granted Servier an exclusive royalty bearing license to develop and commercialize NB S101 (strontium malonate) to treat post menopausal osteoporosis, other bone and joint disorders and dental indications worldwide, except in the U.S. NB S101 is an innovative molecule acting on both bone formation and bone resorption.

Back to news